# Keythera Pharmaceuticals Co., Ltd

> Keythera (Suzhou) Biopharmaceuticals is a clinical-stage biotech building first-in-class small molecule drugs for cancer and autoimmune disease. Its core edge is ADMS - Affinity Detection by Mass Spectroscopy - an affinity-based high-throughput screening platform that can screen up to 250,000 compounds per day per workstation and fuses bioinformatics, structural chemistry, computer-aided drug design and AI to find and optimize drug candidates faster and at lower risk. Founded in 2020 by industry veteran Dr. Yongqi Deng, the company has built six pipelines, advanced its lead EP4 antagonist KF-0210 into the clinic, and raised roughly RMB 100M in Series A funding.

- **Founded:** 2020
- **Headquarters:** Suzhou, Jiangsu, China
- **Founders:** Dr. Yongqi Deng (Founder & CEO)
- **Team size:** ~4-30 employees (sources vary); 85.71% R&D, 100% hold a bachelor's degree or higher, 19% hold doctorates
- **Products:** ADMS - Affinity Detection by Mass Spectroscopy, KF-0210 (EP4 receptor antagonist), Small molecule drug pipeline
- **Notable:** National Finals First Place, 10th China Innovation and Entrepreneurship Competition (Start-up Group), Suzhou 'Unicorn' Incubation Enterprise Award, Top 15 Best Newcomer Award, 2022 China Healthcare Industry Investment and Financing Glory List

## Products & services

- **ADMS - Affinity Detection by Mass Spectroscopy** — An affinity-based high-throughput screening platform capable of screening up to 250,000 compounds per day on each workstation. It integrates bioinformatics, chemical informatics, structural chemistry, computer-aided drug design, combinatorial chemistry and AI to find and optimize small molecule drug candidates while reducing development risk.
- **KF-0210 (EP4 receptor antagonist)** — The company's most advanced program, an EP4 receptor antagonist aimed at treating solid tumors, reported to have reached early clinical (Phase Ib) stage.
- **Small molecule drug pipeline** — Six distinct drug discovery pipelines focused on oncology and autoimmune disease, spanning preclinical to early clinical development.

## Achievements

- National Finals First Place, 10th China Innovation and Entrepreneurship Competition (Start-up Group)
- Suzhou 'Unicorn' Incubation Enterprise Award
- Top 15 Best Newcomer Award, 2022 China Healthcare Industry Investment and Financing Glory List
- Built ADMS platform screening up to 250,000 compounds/day per workstation
- Advanced lead EP4 antagonist KF-0210 into early clinical development

## Latest updates

- **2021-03** — Completed Series A financing of nearly RMB 100M led by Oriza Seed.
- **2022-01** — Recognized among Top 15 Best Newcomers on China Healthcare Industry Investment and Financing Glory List.

## Links

- Website: https://keytherapharma.com/english/
- LinkedIn: https://www.linkedin.com/company/keythera-pharmaceuticals-co-ltd

---

Profile page: https://yespress.io/keythera-pharmaceuticals-co-ltd
Published by YesPress — https://yespress.io
Last updated: 2026-06-08